Home » Stocks » PolarityTE

PolarityTE, Inc. (PTE)

Stock Price: $1.45 USD 0.00 (0.00%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 56.17M
Revenue (ttm) 6.06M
Net Income (ttm) -69.85M
Shares Out 38.74M
EPS (ttm) -2.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $1.45
Previous Close $1.45
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.45
Day's Range 1.40 - 1.52
Day's Volume 294,746
52-Week Range 0.78 - 5.62

More Stats

Market Cap 56.17M
Enterprise Value 31.71M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.74M
Float 25.88M
EPS (basic) -2.35
EPS (diluted) -2.24
FCF / Share -1.43
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.86M
Short Ratio 3.14
Short % of Float 9.79%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.27
PB Ratio 1.40
Revenue 6.06M
Operating Income -73.31M
Net Income -69.85M
Free Cash Flow -55.11M
Net Cash 24.47M
Net Cash / Share 0.63
Gross Margin 52.36%
Operating Margin -1,209.79%
Profit Margin -1,152.60%
FCF Margin -909.32%
ROA -60.69%
ROE -139.78%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.33*
(129.66% upside)
Low
3.00
Current: $1.45
High
4.00
Target: 3.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue5.651.56--6.6934.3747.2713212575.65
Revenue Growth261.61%----80.53%-27.29%-64.27%5.58%65.62%-
Gross Profit3.170.56--3.275.7112.1743.5245.4818.39
Operating Income-93.39-69.43-131-4.10-3.93-13.33-12.243.7111.36-2.11
Net Income-92.49-65.44-131-4.64-3.81-16.20-12.644.616.83-0.97
Shares Outstanding24.9715.264.922.101.231.070.990.950.920.88
Earnings Per Share-3.70-4.29-26.57-2.21-4.93-15.12-12.784.627.14-1.26
EPS Growth--------35.29%--
Operating Cash Flow-56.65-28.55-7.58-1.77-1.61-3.51-4.596.099.42-3.04
Capital Expenditures-2.77-9.22-2.54-0.29-0.35-0.27-0.34-0.47-0.28
Free Cash Flow-59.42-37.77-10.13-1.77-1.32-3.86-4.865.758.95-3.32
Cash & Equivalents29.2470.9617.676.5217.057.4513.3918.0413.698.00
Total Debt3.521.26----1.76-1.245.56
Net Cash / Debt25.7269.7117.676.5217.057.4511.6218.0412.452.45
Assets53.6087.8420.156.7517.6611.4637.6549.3052.3830.03
Liabilities14.686.1815.441.352.005.9117.6019.9629.1418.02
Book Value38.9281.660.175.4015.665.5520.0529.3423.2412.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PolarityTE, Inc.
Country United States
Employees 153
CEO David Seaburg

Stock Information

Ticker Symbol PTE
Stock Exchange NASDAQ
Sector Financial
Industry Closed-End Fund - Equity
Unique Identifier NASDAQ: PTE
IPO Date August 13, 1999

Description

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.